Easterbrook P, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet.1991;337:867-872.
Dickersin K, Min YI. NIH clinical trials and publication bias. Online J Curr Clin Trials.April 28, 1993;doc 50.
Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA.1990;263:1385-1389.
Dickersin K, Min Y-I. Publication bias: the problem that won't go away. Ann N Y Acad Sci.1993;703:135-148.
Dickersin K, Min Y-I, Meinert CL. Factors influencing publication of research results: follow-up of applications
submitted to two institutional review boards. JAMA.1992;267:374-378.
Hetherington J, Dickersin K, Chalmers I, Meinert C. Retrospective and prospective identification of unpublished controlled
trials: lessons from a survey of obstetricians and pediatricians. Pediatrics.1989;84:374-380.
Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented as abstracts: a meta-analysis. JAMA.1994;272:158-162.
Simes RJ. Publication bias: the case for an international registry of clinical
trials. J Clin Oncol.1986;4:1529-1541.
Ioannidis JPA, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on the population distribution
of disease progression rates: an example from populations of trials of human
immunodeficiency virus infection. Am J Epidemiol.1996;144:1074-1085.
Koren G. Bias against negative studies in newspaper reports of medical research. JAMA.1991;266:1824-1826.
Koren G, Graham K, Shear H, Einarson T. Bias against the null hypothesis: the reproductive hazards of cocaine. Lancet.1989;2:1440-1442.
Cooper DA, Gatell JM, Kroon SA.
et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell
counts greater than 400 per cubic millimeter. N Engl J Med.1993;329:297-303.
Volberding PA, Lagakos SW, Koch MA.
et al. Zidovudine in asymptomatic human immunodeficiency virus infection:
a controlled trial in persons with fewer than 500 CD4-positive cells per cubic
millimeter. N Engl J Med.1990;322:941-949.
Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate
and deferred zidovudine in symptom-free HIV infection. Lancet.1994;343:871-881.
Youle MS, Gazzard BG, Johnson MA.
et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival
in patients with advanced HIV disease: a double-blind, placebo controlled
Hersh EM, Brewton G, Abrams D.
et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with
symptomatic HIV infection and AIDS: a randomised, double-blind, placebo-controlled
multicenter study. JAMA.1991;265:1538-1544.
The HIV87 Study Group. Multicenter, randomized, placebo-controlled study of ditiocarb (Imuthiol)
in human immunodeficiency virus-infected asymptomatic and minimally symptomatic
patients. AIDS Res Hum Retroviruses.1993;9:83-89.
Spector SA, McKinley GF, Lalezari JP.
et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons
with AIDS. N Engl J Med.1996;334:1491-1497.
Ioannidis JPA, Cappelleri JC, Sacks HS, Lau J. The relationship between study design, results and reporting of randomized
clinical trials of HIV infection. Control Clin Trials.1997;18:431-444.
Ioannidis JPA, Cappelleri JC, Lau J.
et al. Early or deferred zidovudine therapy in HIV-infected patients without
an AIDS-defining illness: a meta-analysis. Ann Intern Med.1995;122:856-866.
DeMets DL, Fleming TR, Whitley RJ.
et al. The Data and Safety Monitoring Board and acquired immune deficiency
syndrome trials. Control Clin Trials.1995;16:408-421.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics.1979;35:549-556.
Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life sciences: evidence from
a national survey of faculty. JAMA.1997;277:1224-1228.
Rennie D. Thyroid storm. JAMA.1997;277:1238-1243. [published correction appears in JAMA1997;277;1762].
Cappelleri JC, Ioannidis JPA, Schmid CH.
et al. Large trials vs meta-analysis of smaller trials: how do their results
Ioannidis JP, Lau J. The impact of high risk patients on the results of clinical trials. J Clin Epidemiol.1997;50:1089-1098.
Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med.1992;327:248-254.
McIntosh M. The population risk as an explanatory variable in research synthesis
of clinical trials. Stat Med.1996;15:1713-1728.
Ioannidis JP, Lau J. On meta-analyses of meta-analyses. Lancet.1996;348:756.